Home: PCU
1|2003: Frank A Vicini, MD: Select publications
Select publications
Cox JD et al. Consensus statements on radiation therapy
of prostate cancer: Guidelines for prostate re-biopsy after radiation
and for radiation therapy with rising prostate-specific antigen
levels after radical prostatectomy. American Society for Therapeutic
Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17(4):1155.
Abstract
Critz FA. A standard definition of disease freedom is
needed for prostate cancer: Undetectable prostate specific antigen
compared with the American Society of Therapeutic Radiology and
Oncology consensus definition. J Urol 2002;167(3):1310-3.
Abstract
Hanlon AL, Hanks GE. Scrutiny of the ASTRO consensus definition
of biochemical failure in irradiated prostate cancer patients demonstrates
its usefulness and robustness. American Society for Therapeutic
Radiology and Oncology. Int J Radiat Oncol Biol Phys 2000;46(3):559-66.
Abstract
Hodgson DC et al. The impact of irregularly rising prostate-specific
antigen and "impending failure" on the apparent outcome
of localized prostate cancer following radiotherapy. Int
J Radiat Oncol Biol Phys 2001;49(4):957-63. Abstract
Kattan MW et al. The definition of biochemical failure
in patients treated with definitive radiotherapy. Int J
Radiat Oncol Biol Phys 2000;48(5):1469-74. Abstract
Kestin LL et al. Pathologic evidence of dose-response
and dose-volume relationships for prostate cancer treated with combined
external beam radiotherapy and high-dose-rate brachytherapy.
Int J Radiat Oncol Biol Phys 2002;54(1):107-18. Abstract
Kestin LL et al. Practical application of biochemical
failure definitions: What to do and when to do it. Int
J Radiat Oncol Biol Phys 2002;53(2):304-15. Abstract
Martinez AA et al. Dose escalation using conformal high-dose-rate
brachytherapy improves outcome in unfavorable prostate cancer. Int
J Radiat Oncol Biol Phys 2002;53(2):316-27. Abstract
Martinez AA et al. Interim report of image-guided conformal
high-dose-rate brachytherapy for patients with unfavorable prostate
cancer: The William Beaumont Phase II dose-escalating trial.
Int J Radiat Oncol Biol Phys 2000;47(2):343-52. Abstract
Vicini FA et al. Use of conformal high-dose rate brachytherapy
for management of patients with prostate cancer: Optimizing dose
escalation. Tech Urol 2000;6(2):135-45. Abstract
|
